Dynavax Technologies Future Growth
Future criteria checks 4/6
Dynavax Technologies is forecast to grow earnings and revenue by 39.4% and 17.6% per annum respectively while EPS is expected to grow by 37.2% per annum.
Key information
39.4%
Earnings growth rate
37.2%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | 17.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 08 Nov 2024 |
Recent future growth updates
Recent updates
Dynavax Technologies: What The Stock Buyback Means, What It Doesn't
Nov 13Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Nov 12Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Oct 12Dynavax Technologies: Slow And Steady Wins The Race
Sep 05Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Aug 23Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Aug 14Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 384 | 70 | 69 | 96 | 4 |
12/31/2025 | 332 | 48 | 40 | 72 | 5 |
12/31/2024 | 277 | 26 | 7 | 18 | 5 |
9/30/2024 | 261 | 20 | 23 | 27 | N/A |
6/30/2024 | 250 | 17 | 35 | 39 | N/A |
3/31/2024 | 236 | 9 | 53 | 56 | N/A |
12/31/2023 | 232 | -6 | 96 | 101 | N/A |
9/30/2023 | 361 | 61 | 118 | 122 | N/A |
6/30/2023 | 459 | 111 | 147 | 152 | N/A |
3/31/2023 | 656 | 236 | 134 | 141 | N/A |
12/31/2022 | 723 | 293 | 56 | 63 | N/A |
9/30/2022 | 733 | 320 | 140 | 148 | N/A |
6/30/2022 | 674 | 228 | 142 | 153 | N/A |
3/31/2022 | 470 | 104 | 238 | 247 | N/A |
12/31/2021 | 439 | 72 | 326 | 336 | N/A |
9/30/2021 | 258 | -39 | 192 | 199 | N/A |
6/30/2021 | 163 | -6 | 101 | 105 | N/A |
3/31/2021 | 113 | -62 | -31 | -27 | N/A |
12/31/2020 | 40 | -75 | -103 | -92 | N/A |
9/30/2020 | 38 | -97 | -112 | -100 | N/A |
6/30/2020 | 35 | -138 | -115 | -94 | N/A |
3/31/2020 | 40 | -129 | -136 | -108 | N/A |
12/31/2019 | 35 | -156 | -151 | -121 | N/A |
9/30/2019 | 30 | -159 | -161 | -132 | N/A |
6/30/2019 | 21 | -163 | -166 | -144 | N/A |
3/31/2019 | 14 | -160 | -157 | -141 | N/A |
12/31/2018 | 8 | -159 | -146 | -131 | N/A |
9/30/2018 | 3 | -146 | -130 | -115 | N/A |
6/30/2018 | 1 | -128 | N/A | -99 | N/A |
3/31/2018 | 0 | -109 | N/A | -82 | N/A |
12/31/2017 | 0 | -95 | N/A | -78 | N/A |
9/30/2017 | 8 | -89 | N/A | -86 | N/A |
6/30/2017 | 8 | -102 | N/A | -97 | N/A |
3/31/2017 | 10 | -111 | N/A | -105 | N/A |
12/31/2016 | 11 | -112 | N/A | -107 | N/A |
9/30/2016 | 4 | -118 | N/A | -103 | N/A |
6/30/2016 | 5 | -113 | N/A | -97 | N/A |
3/31/2016 | 4 | -108 | N/A | -96 | N/A |
12/31/2015 | 4 | -107 | N/A | -93 | N/A |
9/30/2015 | 6 | -102 | N/A | -88 | N/A |
6/30/2015 | 7 | -102 | N/A | -88 | N/A |
3/31/2015 | 8 | -103 | N/A | -87 | N/A |
12/31/2014 | 11 | -91 | N/A | -74 | N/A |
9/30/2014 | 12 | -90 | N/A | -69 | N/A |
6/30/2014 | 12 | -76 | N/A | -58 | N/A |
3/31/2014 | 13 | -68 | N/A | -51 | N/A |
12/31/2013 | 11 | -75 | N/A | -59 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DVAX's forecast earnings growth (39.4% per year) is above the savings rate (2.6%).
Earnings vs Market: DVAX's earnings (39.4% per year) are forecast to grow faster than the US market (15.2% per year).
High Growth Earnings: DVAX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: DVAX's revenue (17.6% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: DVAX's revenue (17.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DVAX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 09:53 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dynavax Technologies Corporation is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Elemer Piros | Cantor Fitzgerald & Co. |
Joshua Schimmer | Evercore ISI |
Jonathan Miller | Evercore ISI |